Ligand strikes deal to buy struggling Neurogen

Three months after slashing half of its workforce and shelving research work, Neurogen has agreed to be bought out by Ligand Pharmaceuticals for $11 million in stock and the chance to earn millions more in milestones. The acquisition deal gives Ligand a partnership with Merck covering a pain therapy now in clinical trials. Release | Report